Nationwide Fund Advisors increased its stake in Spark Therapeutics, Inc. (NASDAQ:ONCE) by 2.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 17,298 shares of the biotechnology company’s stock after buying an additional 414 shares during the period. Nationwide Fund Advisors’ holdings in Spark Therapeutics were worth $923,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. Fox Run Management L.L.C. bought a new position in Spark Therapeutics during the first quarter valued at approximately $944,000. Teachers Advisors LLC increased its position in Spark Therapeutics by 16.8% in the fourth quarter. Teachers Advisors LLC now owns 33,884 shares of the biotechnology company’s stock valued at $1,691,000 after buying an additional 4,875 shares during the period. UBS Asset Management Americas Inc. increased its position in Spark Therapeutics by 6.1% in the fourth quarter. UBS Asset Management Americas Inc. now owns 185,036 shares of the biotechnology company’s stock valued at $9,233,000 after buying an additional 10,616 shares during the period. Norges Bank bought a new position in Spark Therapeutics during the fourth quarter valued at approximately $8,232,000. Finally, Guggenheim Capital LLC bought a new position in Spark Therapeutics during the fourth quarter valued at approximately $2,413,000. 89.00% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Spark Therapeutics, Inc. (NASDAQ ONCE) opened at 58.51 on Friday. Spark Therapeutics, Inc. has a 1-year low of $35.07 and a 1-year high of $65.99. The stock’s market cap is $1.82 billion. The company’s 50-day moving average is $55.74 and its 200-day moving average is $56.40.
Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Tuesday, May 9th. The biotechnology company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by $0.34. Spark Therapeutics had a negative return on equity of 44.06% and a negative net margin of 745.48%. The business had revenue of $1.27 million for the quarter, compared to analyst estimates of $1.35 million. During the same period last year, the firm earned ($0.95) EPS. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. Equities analysts expect that Spark Therapeutics, Inc. will post ($6.90) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was originally published by WKRB News and is owned by of WKRB News. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.wkrb13.com/markets/2229533/nationwide-fund-advisors-acquires-414-shares-of-spark-therapeutics-inc-once.html.
Several research firms have recently commented on ONCE. ValuEngine downgraded shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 20th. Zacks Investment Research downgraded shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Wedbush reissued an “underperform” rating and issued a $28.00 target price on shares of Spark Therapeutics in a report on Wednesday, May 10th. Cantor Fitzgerald set a $94.00 target price on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Tuesday, May 9th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $59.00 target price on shares of Spark Therapeutics in a report on Wednesday, April 26th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $68.31.
In other news, CFO Stephen W. Webster sold 10,000 shares of Spark Therapeutics stock in a transaction on Tuesday, April 25th. The stock was sold at an average price of $55.18, for a total transaction of $551,800.00. Following the transaction, the chief financial officer now owns 4,398 shares in the company, valued at approximately $242,681.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel Barge Joseph La sold 5,000 shares of Spark Therapeutics stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $55.00, for a total value of $275,000.00. Following the transaction, the general counsel now owns 9,567 shares in the company, valued at approximately $526,185. The disclosure for this sale can be found here. In the last quarter, insiders have sold 38,958 shares of company stock worth $2,138,111. Insiders own 7.30% of the company’s stock.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics, Inc. (NASDAQ:ONCE).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229533/nationwide-fund-advisors-acquires-414-shares-of-spark-therapeutics-inc-once.html
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.